Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.
Brian Mullan
Advertisement
Brian Mullan is the chief technical officer of Yposkesi, an SK Pharmteco company.
Articles by Brian Mullan
Advertisement
Latest Updated Articles
Choosing the Right CDMO for CGT ProgramsPublished: October 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
Turning Real-World Data into Actionable Drug Development Insights With AI
4
The Key Trends Driving Supply Chain Localization and Data Scrutiny in Biopharma
5
